30101060|t|Left lateralized cerebral glucose metabolism declines in amyloid-beta positive persons with mild cognitive impairment.
30101060|a|Background: Previous publications indicate that Alzheimer's Disease (AD) related cortical atrophy may develop in asymmetric patterns, with accentuation of the left hemisphere. Since fluorodeoxyglucose positron emission tomography (FDG PET) measurements of the regional cerebral metabolic rate of glucose (rCMRgl) provide a sensitive and specific marker of neurodegenerative disease progression, we sought to investigate the longitudinal pattern of rCMRgl in amyloid-positive persons with mild cognitive impairment (MCI) and dementia, hypothesizing asymmetric declines of cerebral glucose metabolism. Methods: Using florbetapir PET and cerebrospinal fluid (CSF) measures to define amyloid-beta (Abeta) positivity, 40 Abeta negative (Abeta-) cognitively unimpaired controls (CU; 76 +- 5y), 76 Abeta positive (Abeta+) persons with MCI (76 +- 7y) and 51 Abeta + persons with probable AD dementia (75 +- 7y) from the AD Neuroimaging Initiative (ADNI) were included in this study with baseline and 2-year follow-up FDG PET scans. The degree of lateralization of longitudinal rCMRgl declines in subjects with Abeta + MCI and AD in comparison with Abeta- CU were statistically quantified via bootstrapped lateralization indices [(LI); range - 1 (right) to 1 (left)]. Results: Compared to Abeta- CU, Abeta + MCI patients showed marked left hemispheric lateralization (LI: 0.78). In contrast, modest right hemispheric lateralization (LI: -0.33) of rCMRgl declines was found in Abeta + persons with probable AD dementia. Additional comparisons of Abeta + groups (i.e. MCI and probable AD dementia) consequently indicated right hemispheric lateralization (LI: -0.79) of stronger rCMRgl declines in dementia stages of AD. For all comparisons, voxel-based analyses confirmed significant (pFWE<0.05) declines of rCMRgl within AD-typical brain regions. Analyses of cognitive data yielded predominant decline of memory functions in both MCI and dementia stages of AD. Conclusions: These data indicate that in early stages, AD may be characterized by a more lateralized pattern of left hemispheric rCMRgl declines. However, metabolic differences between hemispheres appear to diminish with further progression of the disease.
30101060	26	33	glucose	Chemical	MESH:D005947
30101060	57	69	amyloid-beta	Gene	351
30101060	79	86	persons	Species	9606
30101060	97	117	cognitive impairment	Disease	MESH:D003072
30101060	167	186	Alzheimer's Disease	Disease	MESH:D000544
30101060	188	190	AD	Disease	MESH:D000544
30101060	200	216	cortical atrophy	Disease	MESH:D001284
30101060	301	319	fluorodeoxyglucose	Chemical	MESH:D019788
30101060	350	353	FDG	Chemical	MESH:D019788
30101060	415	422	glucose	Chemical	MESH:D005947
30101060	424	430	rCMRgl	Chemical	-
30101060	475	500	neurodegenerative disease	Disease	MESH:D019636
30101060	567	573	rCMRgl	Chemical	-
30101060	594	601	persons	Species	9606
30101060	612	632	cognitive impairment	Disease	MESH:D003072
30101060	634	637	MCI	Disease	MESH:D060825
30101060	643	651	dementia	Disease	MESH:D003704
30101060	699	706	glucose	Chemical	MESH:D005947
30101060	734	745	florbetapir	Chemical	MESH:C545186
30101060	799	811	amyloid-beta	Gene	351
30101060	813	818	Abeta	Gene	351
30101060	835	840	Abeta	Gene	351
30101060	851	856	Abeta	Gene	351
30101060	910	915	Abeta	Gene	351
30101060	926	931	Abeta	Gene	351
30101060	934	941	persons	Species	9606
30101060	947	950	MCI	Disease	MESH:D060825
30101060	969	974	Abeta	Gene	351
30101060	977	984	persons	Species	9606
30101060	999	1010	AD dementia	Disease	MESH:D000544
30101060	1031	1033	AD	Disease	MESH:D000544
30101060	1128	1131	FDG	Chemical	MESH:D019788
30101060	1188	1194	rCMRgl	Chemical	-
30101060	1221	1226	Abeta	Gene	351
30101060	1229	1232	MCI	Disease	MESH:D060825
30101060	1237	1239	AD	Disease	MESH:D000544
30101060	1259	1264	Abeta	Gene	351
30101060	1399	1404	Abeta	Gene	351
30101060	1410	1415	Abeta	Gene	351
30101060	1418	1421	MCI	Disease	MESH:D060825
30101060	1422	1430	patients	Species	9606
30101060	1557	1563	rCMRgl	Chemical	-
30101060	1586	1591	Abeta	Gene	351
30101060	1594	1601	persons	Species	9606
30101060	1616	1627	AD dementia	Disease	MESH:D000544
30101060	1655	1660	Abeta	Gene	351
30101060	1676	1679	MCI	Disease	MESH:D060825
30101060	1693	1704	AD dementia	Disease	MESH:D000544
30101060	1786	1792	rCMRgl	Chemical	-
30101060	1805	1813	dementia	Disease	MESH:D003704
30101060	1824	1826	AD	Disease	MESH:D000544
30101060	1916	1922	rCMRgl	Chemical	-
30101060	1930	1932	AD	Disease	MESH:D000544
30101060	2003	2030	decline of memory functions	Disease	MESH:D008569
30101060	2039	2042	MCI	Disease	MESH:D060825
30101060	2047	2055	dementia	Disease	MESH:D003704
30101060	2066	2068	AD	Disease	MESH:D000544
30101060	2125	2127	AD	Disease	MESH:D000544
30101060	2199	2205	rCMRgl	Chemical	-
30101060	Association	MESH:D008569	351
30101060	Association	MESH:D003072	351
30101060	Association	MESH:D005947	MESH:D019636
30101060	Association	MESH:D060825	351
30101060	Association	MESH:D019788	MESH:D019636
30101060	Association	MESH:D005947	MESH:D003072
30101060	Association	MESH:D000544	351
30101060	Association	MESH:C545186	351
30101060	Association	MESH:D005947	351

